Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1999, for ISIS Pharmaceuticals, Inc. (Note: The input metadata lists "IONIS PHARMACEUTICALS INC," but the filing text explicitly identifies the registrant as ISIS Pharmaceuticals, Inc., a biopharmaceutical company focused on antisense drug discovery and development). The company is not yet profitable and relies on collaborative research agreements, grants, and interest income to fund operations.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Revenue (Collaborative R&D) | $6.6 million | $5.8 million |
| Net Loss | $(12.6) million | $(11.5) million |
| Loss Per Share (Basic/Diluted) | $(0.46) | $(0.43) |
| Cash and Cash Equivalents (End of Period) | $20.3 million | $27.8 million |
| Short-term Investments | $22.5 million | N/A (Not listed separately in 1998 summary) |
| Total Liquidity (Cash + Short-term Inv) | $42.9 million | $58.8 million (Dec 31, 1998) |
| Working Capital | $29.2 million | $40.7 million (Dec 31, 1998) |
| Long-term Debt (Carrying Amount) | $82.6 million | $81.3 million (Dec 31, 1998) |
| Cash Used in Operations | $(14.0) million | $(16.3) million |
Material Changes vs. Prior Period
- Revenue Growth: Collaborative revenue increased 14% to $6.6 million, driven by new partnerships with Zeneca Limited, Merck & Company, and Abbott Laboratories.
- Expense Increases: General and administrative expenses rose to $2.8 million from $1.9 million due to additional staffing and outside services. Interest expense increased to $2.7 million from $1.7 million, primarily due to a $15 million follow-on private debt financing in Q2 1998.
- Liquidity Decline: Cash and short-term investments decreased from $58.8 million (Dec 31, 1998) to $42.9 million (Mar 31, 1999) due to funding operating losses, capital equipment investments, and debt principal payments.
- Net Loss Expansion: Net loss widened to $12.6 million from $11.5 million year-over-year.
Guidance, Outlook, and Risks
- Outlook: Management expects operating losses to continue and increase for several years as R&D activities expand. The company believes current liquidity is sufficient to meet requirements through the end of 2000.
- Subsequent Event: In April 1999, ISIS formed a joint venture, Orasense Ltd., with Elan Pharmaceuticals to develop oral delivery technology for antisense drugs. Elan purchased $15 million of common stock and $12 million of preferred stock.
- Debt Structure: The company has $40 million in private long-term debt (accruing to $78 million by 2002) with no principal or interest payments required until 2003. A $40 million line of credit with Boehringer Ingelheim was unavailable as of March 31, 1999, but is expected to be available before year-end.
- Year 2000 Risk: The company estimates remediation costs will not exceed $500,000. Primary risk exposure is reliance on commercial utilities (water/power) which could halt R&D for 3-6 months if providers fail to comply.
- Regulatory: The company received FDA approval in late 1998 to market Vitravene(TM) for CMV retinitis.
Investor Verification Checklist
- Verify the status and availability of the $40 million Boehringer Ingelheim line of credit.
- Confirm the timeline for the Orasense Ltd. joint venture funding and technology transfer.
- Monitor the progress of Year 2000 remediation for critical third-party vendors and utility providers.
- Review the burn rate of cash relative to the projected runway through 2000.
- Assess the impact of the $15 million Elan investment on future dilution and preferred stock conversion terms.